10-Q: Curanex Q3 Loss Widens on R&D, Faces Nasdaq Delisting Risk

Curanex Pharmaceuticals reported a significantly increased net loss in Q3 2025 due to substantial R&D investments following its IPO, while also receiving a Nasdaq non-compliance notice for its share price.

Summary

• Net loss for the three months ended September 30, 2025, increased to $954,059, compared to $91,166 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $1,151,988, up from $215,567 for the nine months ended September 30, 2024.
• Cash and cash equivalents increased significantly to $5,830,537 as of September 30, 2025, from $148,891 at December 31, 2024, primarily due to proceeds from the IPO.
• The company completed its Initial Public Offering (IPO) on August 27, 2025, raising net proceeds of approximately $13.24 million, with an additional $2.07 million from the underwriters' over-allotment option.
• Research and Development (R&D) expenses totaled $677,474 for Q3 2025 and $679,574 for the nine months ended September 30, 2025, primarily for FDA-mandated IND-enabling studies.
• Prepaid R&D expenses amounted to $8,472,593 as of September 30, 2025, representing advance payments to Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).
• Received a Nasdaq non-compliance notice on November 5, 2025, for failing to maintain a minimum bid price of $1.00, with a compliance period extending until May 4, 2026.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.

Sentiment

Score: 3

Explanation: While the company successfully completed its IPO and has a strong cash position, the significantly increased net losses, the Nasdaq non-compliance notice, and the ineffective disclosure controls indicate substantial operational and governance challenges. The early stage of drug development also presents high inherent risk.

Positives

• Successful completion of the Initial Public Offering (IPO) and the underwriters' over-allotment option exercise, raising total net proceeds of approximately $15.31 million.
• A strong cash position of $5,830,537 as of September 30, 2025, which has alleviated prior substantial doubt about the company's ability to continue as a going concern.
• Significant investment in Research and Development (R&D), with $677,474 in Q3 2025, advancing the lead candidate Phyto-N towards Investigational New Drug (IND) submission.
• Full repayment of $400,000 in related-party shareholder loans, eliminating associated debt and interest obligations.

Negatives

• Net loss significantly increased to $954,059 for the three months ended September 30, 2025, and $1,151,988 for the nine months ended September 30, 2025, compared to prior periods.
• Received a Nasdaq non-compliance notice on November 5, 2025, due to the common stock's closing bid price falling below the $1.00 minimum requirement.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, indicating a material weakness in internal controls.
• General and administrative expenses increased due to IPO-related and public company readiness costs.
• Provisional patent applications acquired from a related party expired on March 18, 2025, although a PCT application was filed combining some of these.

Risks

• Risk of delisting from The Nasdaq Capital Market if the common stock does not regain a minimum bid price of $1.00 for at least ten consecutive business days by May 4, 2026, or within any extended compliance period.
• Inherent risks associated with drug development, including the uncertainty of successful preclinical and clinical trials, regulatory approvals, and eventual commercialization or strategic licensing agreements.
• Reliance on external funding for future operations beyond the next twelve months, as the company anticipates continued operating losses.
• Ineffective disclosure controls and procedures, which could lead to material information not being reported timely or accurately, potentially impacting investor confidence and regulatory compliance.
• Dependence on Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) for critical R&D activities, introducing third-party execution risks.
• Cash balances periodically exceeding Federal Deposit Insurance Corporation (FDIC) insurance limits, posing a risk if underlying financial institutions fail or face adverse conditions.

Future Outlook

The company anticipates continued operating losses in the foreseeable future as it focuses on advancing its lead product candidate, Phyto-N, through FDA-required preclinical studies and towards an Investigational New Drug (IND) application. R&D spending is expected to remain significant but moderate in future periods until FDA approvals are obtained and clinical trial activities commence. The company aims to generate revenue only upon successful commercialization of its product candidates or from entering into strategic licensing agreements, though the timing or likelihood of these events is uncertain. Management believes existing cash and access to shareholder support are sufficient to fund operations for at least the next twelve months, but further funding will be required for operations beyond this period.

Management Comments

• Our business strategy is centered on developing innovative botanical drugs, with a focus on Phyto-N as our lead candidate, for the treatment of inflammatory diseases.
• By leveraging our founders' expertise in botanical medicine, pursuing strategic partnerships, implementing efficient development processes, building a strong IP portfolio, fostering a culture of innovation, and maintaining focus and adaptability, we aim to establish Curanex as a leader in the field and create significant value for patients as well as our stockholders.
• If successfully developed and approved, Phyto-N may improve the lives of many patients worldwide.
• Our research to date has been limited to preclinical studies for each of these indications.
• We expect R&D spending to remain significant as these studies progress but to moderate in future periods until FDA approvals are obtained and clinical trial activities commence.
• Management believes existing cash and access to shareholders support are sufficient to fund our operations for at least the next twelve months.
• Management believes that substantial doubt [about going concern] has been alleviated due to our strong cash position, receipt of the IPO proceeds.
• Our management does not expect that our disclosure controls and procedures will prevent all error and all fraud.

Industry Context

Curanex Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting inflammatory diseases with botanical drugs. The significant increase in R&D expenses post-IPO is typical for a development-stage biotech company advancing preclinical programs towards clinical trials. The focus on FDA-mandated IND-enabling studies for conditions like ulcerative colitis and atopic dermatitis aligns with a broader industry trend of addressing unmet medical needs in chronic inflammatory conditions. However, the company's reliance on botanical drugs, while potentially offering a unique market niche, also presents specific regulatory and scientific challenges compared to traditional synthetic compounds. The Nasdaq non-compliance issue highlights the volatility and scrutiny faced by smaller, early-stage public companies in this sector.

Comparison to Industry Standards

• The company's current stage, with research limited to preclinical studies for its lead candidate Phyto-N, is typical for a newly public, early-stage biopharmaceutical company.
• The substantial increase in R&D spending post-IPO, with $677,474 in Q3 2025, is consistent with industry benchmarks for companies initiating FDA-mandated IND-enabling studies, which are crucial steps before human clinical trials.
• The accumulated deficit of $(1,774,437) and recurring net losses are common for pre-revenue biotech firms heavily investing in drug development, similar to small-cap biotechs focused on specific disease areas.
• The successful IPO and subsequent cash position of $5.8 million provide a critical financial runway, a common milestone for early-stage biotechs, comparable to capital raises seen by peers like Xencor (XNCR) or other emerging biopharmaceutical companies.
• The Nasdaq non-compliance for minimum bid price is a frequent challenge for smaller, newly listed companies, particularly in the biotech sector where stock prices can be highly volatile and sensitive to development milestones and market sentiment. Many small-cap biotechs face similar delisting threats, often requiring reverse stock splits to regain compliance.
• The identified ineffectiveness of disclosure controls and procedures is a significant governance concern that deviates from best practices for public companies, regardless of size, and is an area where more mature companies like Amgen (AMGN) or Pfizer (PFE) maintain robust internal control frameworks.

Corporate Governance

Related Party Transactions

• On June 17, 2024, the company entered into an Asset Purchase Agreement with Duraviva Pharma Inc., a related party, to acquire IP Assets (provisional patent applications, R&D animal studies) in exchange for 23,400,000 common shares and $730,000 consideration.
• On January 1, 2025, the company assumed an office lease from Duraviva Pharma Inc., a related party.
• In February and May 2025, the company received two $200,000 loans from Dian Ying Jing, a founder, Secretary, and wife of the CEO, Jun Liu. These loans, totaling $400,000, accrued interest at 4.34% per annum and were fully repaid in September 2025, including $8,537.32 in accrued interest.

Stakeholder Impact

• Shareholders: Significant dilution from the IPO, increased net losses, and the Nasdaq non-compliance notice could negatively impact share value and investor confidence. The issuance of super voting preferred stock concentrates voting power.
• Employees: Continued R&D investment suggests job stability for R&D personnel, but overall financial performance and Nasdaq listing status could create uncertainty.
• Customers: Currently pre-revenue, so there is no direct customer impact. Future patients could potentially benefit if Phyto-N is successfully developed and commercialized.
• Suppliers/Creditors: The repayment of related-party loans is positive. Increased R&D spending indicates more business for Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).
• Regulatory Authorities (FDA/Nasdaq): Active engagement with the FDA for IND studies is ongoing. The Nasdaq non-compliance requires a clear plan and execution to regain listing standards.

Next Steps

• Continue development of the lead product candidate, Phyto-N, for the treatment of ulcerative colitis.
• Conduct FDA-required good laboratory practice (GLP) toxicology and pharmacokinetic studies for Phyto-N.
• Prepare and submit an Investigational New Drug (IND) application.
• Regain compliance with Nasdaq's minimum bid price requirement by May 4, 2026, potentially through a reverse stock split.
• Address and improve the effectiveness of disclosure controls and procedures.
• Evaluate the impact of ASU 2024-03 on financial statement disclosures.

Key Dates

Recommendation

The company faces significant headwinds despite its recent IPO. The substantial increase in net losses, coupled with the Nasdaq non-compliance notice and the acknowledged ineffectiveness of disclosure controls, points to considerable operational and governance risks. While the IPO provided a cash infusion, the company remains pre-revenue with a long and uncertain path to commercialization for its drug candidates. The expiration of provisional patents and the early stage of R&D (preclinical) further underscore the high-risk profile. The Nasdaq delisting threat adds immediate pressure and uncertainty, making the stock a high-risk investment with a negative outlook in the short to medium term.

Keywords

Curanex Pharmaceuticals, CURX, 10-Q, Q3 2025, Financial Results, Net Loss, IPO, Nasdaq Compliance, R&D Expenses, Botanical Drugs, Inflammatory Diseases, Phyto-N, Ulcerative Colitis, Atopic Dermatitis, SEC Filing, Biotechnology, Pharmaceuticals, Going Concern, Disclosure Controls